Cinacalcet: A pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease

PharmacoEconomics

Volumn 29, Issue 9, 2011, Pages 807-821

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Cinacalcet, therapeutic use; Dialysis; Hyperparathyroidism; Kidney disorders, contributory factors; Secondary hyperparathyroidism, treatment

Indexed keywords

CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D;

CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE UTILIZATION; HUMAN; KIDNEY FAILURE; MYALGIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

CALCIUM; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS;

EID: 80051722368     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11207220-000000000-00000     Document Type: Review

References (76)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 Oct; 42 (4 Suppl. 3): S1-201
2. Salem MM. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis 1997; 29: 862-5
3. Owda A, Elhwairis H, Narra S, et al. Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail 2003; 25: 595-602
4. United States Renal Data System (USRDS). The concise 2010 annual data report atlas of chronic kidney disease & end-stage renal disease in the United States [online]. Available from URL: Http://www.usrds.org/2010/ADR- booklet-2010-lowres.pdf [Accessed 2011 Jun 20]
5. MacReady N. Skyrocketing costs of dialysis may require difficult decisions. Renal week 2009: American Society of Nephrology (ASN) 2009 Annual Meeting, San Diego CA [media release] [online]. Available from URL: Http:// www.medscape.com/viewarticle/712019 [Accessed 2011 Jun 6]
6. De Boer IH, Gorodetskaya I, Young B, et al. The severity of secondary hyperparathyroidismin chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-9
7. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-8
8. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manage Care Pharm 2007 Jun; 13 (5): 397-411
9. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999; 73: S14-9
10. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333: 166-74
11. Goodman WG, Goldin J, Kuizon BD, et al. Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83
12. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: A link between endstage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
13. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca • PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8
14. Krasniak A, Drozdz M, Pasowicz M, et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007; 22: 515-21
15. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-66
16. BlockGA,Hulbert-Shearon TE, LevinNW, et al. Association of serum phosphorous and calcium• phosphorous product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31 (4): 607-17
17. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-18
18. Danese MD, Belozeroff V, Smirnakis K, et al. consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008 Sep; 3 (5): 1423-9
19. Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and metaanalysis. JAMA 2011 Mar 16; 305 (11): 1119-27
20. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1-130
21. Schmid H, Schiffl H, Lederer SR. Pharmacotherapy of endstage renal disease. Expert Opin Pharmacother 2010 Mar; 11 (4): 597-613
22. Dumasius V, Angelos P. Parathyroid surgery in renal failure patients. Otolaryngol Clin North Am 2010 Apr; 43 (2): 433-40, x-xi
23. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 34-8
24. Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant 2004; 19 Suppl. 5: V15-9
25. Goldsmith DR, Scott LJ, Cvetkovic RS, et al. Sevelamer hydrochloride: A rivew of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 2008; 68 (1): 85-104
26. Drueke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 2009; 4 (1): 234-41
27. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: Rationale for use and results from clinical trials. Pediatr Nephrol 2003 Dec; 18 (12): 1206-10
28. Amgen Ltd. Cinacalcet (Mimpara®) summary of product characteristics [online]. Available from URL: Http://www. medicines.org.uk/emc/medicine/15432 [Accessed 2011Mar 23]
29. Amgen Inc. Cinacalcet (Sensipar®) US prescribing information [online]. Available from URL: Http://pi.amgen.com/ united-states/sensipar/ sensipar-pi-hcp-english.pdf [Accessed 2011 Mar 23]
30. Red Book 2010 edition. USA: Thomson Reuters (Healthcare) Inc, 2010
31. British Medical Association and Royal Pharmaceutical Society. British National Formulary 61st edition. London: BMJ Group and Pharmaceutical Press, 2011 Mar
32. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 Apr 8; 350 (15): 1516-25
33. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 67: 760-71
34. Moe SM,ChertowGM,Coburn JW, et al.AchievingNKF-K/ DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005 Feb; 67 (2): 760-71
35. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003 Mar; 14 (3): 575-83
36. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agentAMG073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. JAmSocNephrol 2002Apr; 13 (4): 1017-24
37. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium • phosphorus in secondary hyperparathyroidism. Kidney Int 2003 Jan; 63 (1): 248-54
38. Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3 (6): 1718-25
39. Block GA, Zeig S, Sugihara J, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008 Jul; 23 (7): 2311-8
40. Messa P, Macario F, Yaqoob M, et al. The OPTIMA study: Assessing a new cinacalcet (Sinsipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008 Jan; 3 (1): 36-45
41. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005 Oct; 68 (4): 1793-800
42. Cunningham J, Floege J, London G, et al. Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics. NDT Plus 2008; 1 Suppl. 1: I29-35
43. Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010 Sep; 78 (6): 578-89
44. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011 Apr; 26 (4): 1327-39
45. Chertow GM, Pupim LB, Block GA, et al. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol 2007 Sep; 2 (5): 898-905
46. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: A systematic review and economic evaluation. Health Technol Assess 2007; 11 (18): I-xiii, 1-167
47. Belozeroff V, Goodman WG, Ren L, et al. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4 (3): 673-9
48. Garside R, Pitt M, Anderson R, et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: A UK perspective. Nephrol Dial Transplant 2007 May; 22 (5): 1428-36
49. Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: A cost utility analysis. Am J Kidney Dis 2007 Jun; 49 (6): 801-13
50. Ray JA, Borker R, Barber B, et al. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health 2008; 11 (5): 800-8
51. Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010 Nov 1; 28 (11): 1041-54
52. Ravasio R, Giotta N, Marino A, et al. Cost-effectiveness analysis of cinacalcet versus conventional care in the treatment of secondary hyperparathyroidism on chronic haemodialysis patients [in Italian]. Pharmacoeconomics Ital Res Articles 2008 Jan; 10 (1): 13-22
53. Arenas JMD, Rebollo P, Alvarez-Ude F, et al. Is cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis? Nefrologia 2008; 28 (5): 511-6
54. Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010 Dec; 56 (6): 1108-16
55. Ho J, Kwan R, Chiroli S. A cost consequence model to assess the economic impact in Germany of patients achieving KDOQITM targets with the use of a combination of cinacalcet plus traditional therapy compared with TT alone [abstract no. PDB20]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris
56. Dansi F, Chiroli S, Robbins S, et al. A budget impact model to assess the impact on the Italian National Health Service budget of the introduction of Mimpara (cinacalcet) in the new indication primary hyperparathyroidism [abstract no. PDB18]. Value Health 2009; 12 (3): A100
57. Pinto CG, Weigert A, Pissarra I, et al. Cost-effectiveness of cinecalcet in the treatment of secondary hyperparatiroidism (SHPT) [abstract no. PUK5]. Value Health 2008; 11 (3): A301
58. Iannazzo S, Pradelli L, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism (SHPT) in five European countries [abstract no. PUK24]. 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2010 Nov 6-9; Prague
59. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 Jun [online]. Available from URL: Http://www.nice. org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008. pdf [Accessed 2011 Apr 7]
60. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health 2010; 13 (6): 853-6
61. Jönsson B. Changing health environment: The challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10
62. Eichler H-G, Kong SX, Gerth WC, et al. Use of costeffectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7 (5): 518-28
63. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005 Jun; 16 (6): 1788-93
64. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: The USRDS waves 1, 3, and 4 study. Hemodial Int 2007 Jan; 11 (1): 62-71
65. Kim J, Dylan M, Griffith R, et al. Association of elevated parathyroid hormone (PTH) and calcium with risk of hip, vertebral or pelvic fracture in hemodialysis patients [abstract no. SO26]. 41st Congress of the European Renal Association-European Dialysis and Transplant Association; 2004 May 15-18; Lisbon
66. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-6
67. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-93
68. Ray JA, Valentine WJ, Palmer AJ. Cost-utility analysis of cinacalcet in addition to standard of care in the UK [letter]. Nephrol Dial Transplant 2007 Nov; 22 (11): 3355-7; author reply 3357-8
69. Rappange DR, van Baal PH, van Exel NJ, et al. Unrelated medical costs in life-years gained: Should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 2008; 26 (10): 815-30
70. Manns B, Meltzer D, Taub K, et al. Illustrating the impact of including future costs in economic evaluations: An application to end-stage renal disease care. Health Econ 2003 Nov; 12 (11): 949-58
71. Smith DH, Gullion CM, Nichols G, et al. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004 May; 15 (5): 1300-6
72. Cohen E, Uribarri J. Cinacalcet cost and utility in dialysis patients [letter]. Semin Dial 2005; 18 (4): 353-4
73. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003 Jul 28; 163: 1637-41
74. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473-81
75. Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 2008; 26 (7): 589-602
76. Hoyle M. Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics 2011; 29 (1): 1-15